Journal article
Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors
CA: a cancer journal for clinicians, Vol.74(4), pp.359-367
04/29/2024
DOI: 10.3322/caac.21840
PMCID: PMC11938941
PMID: 38685134
Abstract
The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP-NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP-NETs from poorly differentiated neuroendocrine carcinoma. In addition, because of major advancements in diagnostic and therapeutic technologies for GEP-NETs, AJCC version 9 advocates against the use of serum chromogranin A for the diagnosis and monitoring of GEP-NETs. Furthermore, AJCC version 9 recognizes the increasing role of endoscopy and endoscopic resection in the diagnosis and management of NETs, particularly in the stomach, duodenum, and colorectum. Finally, T1NXM0 has been added to stage I in these disease sites as well as in the appendix.
Details
- Title: Subtitle
- Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors
- Creators
- Aman Chauhan - Sylvester Comprehensive Cancer CenterKelley Chan - Loyola University Medical CenterThorvardur R. Halfdanarson - Mayo ClinicAndrew M. Bellizzi - University of IowaGuido Rindi - Università Cattolica del Sacro CuoreDermot O'Toole - Trinity College DublinPhillip S. Ge - The University of Texas MD Anderson Cancer CenterDhanpat Jain - Yale UniversityArvind Dasari - The University of Texas MD Anderson Cancer CenterDaniel A. Anaya - Moffitt Cancer CenterEmily Bergsland - University of California, San FranciscoErik Mittra - Oregon Health & Science UniversityAlice C. Wei - Memorial Sloan Kettering Cancer CenterThomas A. Hope - University of California, San FranciscoAyse T. Kendi - Mayo ClinicSamantha M. Thomas - Duke UniversitySherlonda Flem - The University of Texas MD Anderson Cancer CenterJames Brierley - Princess Margaret Cancer CentreElliot A. Asare - University of UtahKay Washington - Vanderbilt University Medical CenterChanjuan Shi - Duke Medical Center
- Resource Type
- Journal article
- Publication Details
- CA: a cancer journal for clinicians, Vol.74(4), pp.359-367
- DOI
- 10.3322/caac.21840
- PMID
- 38685134
- PMCID
- PMC11938941
- NLM abbreviation
- CA Cancer J Clin
- ISSN
- 0007-9235
- eISSN
- 1542-4863
- Publisher
- Wiley
- Number of pages
- 9
- Grant note
- American Joint Committee on Cancer
- Language
- English
- Electronic publication date
- 04/29/2024
- Academic Unit
- Pathology
- Record Identifier
- 9984623024602771
Metrics
23 Record Views